BIIB-094 is an antisense therapeutic designed to reduce LRRK2 levels through LRRK2 reduction. Antisense therapies work by interfering with the production of specific proteins at the genetic level, thus lowering the amount of LRRK2 protein, which is believed to contribute to Parkinson’s disease progression.
Science-based and high-quality devices
We are providing people with Parkinson’s disease, or who are at risk of getting Parkinson’s disease, with the best tips, tools and insights to prevent or mitigate their disease.
This site does not provide medical advice, diagnosis, or treatment. Before implementing any lifestyle or health change, first consult with a qualified health care professional.
Your cart is currently empty.
Start Shopping
